Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | GART | P22102 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239774 | 0.92 | HCAR3 (0.54) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL15250379 | 0.92 | LMNA (0.54) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL428455 | 0.86 | HCAR3 (0.53) | HCAR3LMNAMAPTALDH1A1GART | |
| SCHEMBL12210248 | 0.83 | LMNA (0.56) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL3633382 | 0.81 | HCAR3 (0.56) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL15239673 | 0.81 | MAPT (0.61) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL3515437 | 0.81 | HCAR3 (0.52) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL4086159 | 0.81 | HCAR3 (0.63) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL15384088 | 0.80 | LMNA (0.44) | HCAR3LMNAMAPTALDH1A1PKM | |
| SCHEMBL13695000 | 0.79 | GART (0.46) | LMNAMAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| CN-110691598-A | Metalloenzyme inhibitor compounds | 赛列尼蒂治疗(百慕大)有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3562487-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2019-01-10 | — | — | US | disclosed |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-10-02 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | HCAR3 3456/4885LMNA 3098/4885MAPT 995/4885 |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | HCAR3 4684/4885LMNA 3671/4885MAPT 2593/4885 |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | HCAR3 4591/4885LMNA 4166/4885MAPT 2388/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | HCAR3 4012/4885LMNA 3168/4885MAPT 2173/4885 |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | HCAR3 4591/4885LMNA 4166/4885MAPT 2388/4885 |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | HCAR3 4591/4885LMNA 4166/4885MAPT 2388/4885 |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | HCAR3 4591/4885LMNA 4166/4885MAPT 2388/4885 |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | HCAR3 4591/4885LMNA 4166/4885MAPT 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.